Disease-modifying therapies in multiple sclerosis in Latin America

about

Disease-modifying therapies in multiple sclerosis in Latin America

Item

http://www.wikidata.org/entity/Q42365146

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Disease-modifying therapies in multiple sclerosis in Latin America

@en

Disease-modifying therapies in multiple sclerosis in Latin America

@nl

type

Item

label

Disease-modifying therapies in multiple sclerosis in Latin America

@en

Disease-modifying therapies in multiple sclerosis in Latin America

@nl

prefLabel

Disease-modifying therapies in multiple sclerosis in Latin America

@en

Disease-modifying therapies in multiple sclerosis in Latin America

@nl

P1476

Disease-modifying therapies in multiple sclerosis in Latin America

@en

P2093

Eli Skromne-Eisenberg

http://www.w3.org/2001/XMLSchema#string

Irene Treviño-Frenk

http://www.w3.org/2001/XMLSchema#string

Laura Ordoñez-Boschetti

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Multiple sclerosis care in Latin America

Access and barriers to MS care in Latin America.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis.

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate

P304

2055217317723369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2055217317723369

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28979794

http://www.w3.org/2001/XMLSchema#string

P932

5617092

http://www.w3.org/2001/XMLSchema#string